Bang YJ, Su WC, Schuler M, Nam DH, Lim WT, Bauer TM, Azaro A, Poon RTP, Hong D, Lin CC, Akimov M, Ghebremariam S, Zhao S, Giovannini M, Ma B. Phase 1 study of Capmatinib in MET-positive solid tumor patients: dose escalation and expansion of selected cohorts. Cancer Sci, 2020; 111(2):536-47. https://doi.org/10.1111/cas.14254 |
|
Baltschukat S, Engstler BS, Huang A, Hao HX, Tam A, Wang HQ, Liang J, DiMare MT, Bhang HC, Wang Y, Furet P, Sellers WR, Hofmann F, Schoepfer J, Tiedt R. Capmatinib (INC280) is active against models of non-small cell lung cancer and other cancer types with defined mechanisms of MET activation. Clin Cancer Res, 2019; 25(10):3164-75. https://doi.org/10.1158/1078-0432.CCR-18-2814 | |
|
Bhatt D, Rajkamal B. A UPLC-MS/MS method development and validation for the estimation of sofosbuvir from human plasma. Int J Appl Pharm, 2017; 9(1):30-6. https://doi.org/10.22159/ijap.2017v9i1.15652 | |
|
Capmatinib (Rx)-Medscape. Available via https://reference. medscape.com/drug/tabrecta-capmatinib-4000068 | |
|
EMA. Guideline on bioanalytical method validation. 2011. Canary Wharf, London E14 5EU, United Kingdom. | |
|
Esaki T, Hirai F, Makiyama A, Seto T, Bando H, Naito Y, Yoh K, Ishihara K, Kakizume T, Natsume K, Myers A, Doi T. Phase I dose escalation study of Capmatinib (INC280) in Japanese patients with advanced solid tumors. Cancer Sci, 2019; 110(4):1340-51. https://doi.org/10.1111/cas.13956 | |
|
Fan X, Yang G, Cui W, Liu Q, Zhang Z, Zhang Z. Development and full validation of an LC-MS/MS methodology to quantify capmatinib (INC280) following intragastric administration to rats. Biomed Chromatogr, 2020; 34:e4768. https://doi.org/10.1002/bmc.4768 | |
|
FDA. FDA guidance for industry: bioanalytical method validation. US Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), 2001. | |
|
FDA. FDA grants accelerated approval to Capmatinib for metastatic non-small cell lung cancer-highlights of prescribing information. US Food and Drug Administration (FDA), 2020. Available via https://www. accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf | |
|
Glaenzel U, Jin Y, Hansen R, Schroer K, Rahmanzadeh G, Pfaar U, van Lier JJ, Borell H, Meissner A, Camenisch G, Zhao S. Absorption, distribution, metabolism, and excretion of Capmatinib (INC280) in HEalthy male volunteers and in vitro aldehyde oxidase phenotyping of the major metabolite. Drug Metab Dispos, 2020; 48(10):873-85. https://doi.org/10.1124/dmd.119.090324 | |
|
He G, Mai L, Wang X. Development and validation of an HPLC-MS/MS method for rapid simultaneous determination of cefprozil diastereomers in human plasma. Int J Anal Chem, 2018; 6959761:1-9. https://doi.org/10.1155/2018/6959761 | |
|
Liu X, Wang Q, Yang G, Marando C, Koblish HK, Hall LM, Fridman JS, Behshad E, Wynn R, Li Y, Boer J, Diamond S, He C, Xu M, Zhuo J, Yao W, Newton RC, Scherle PA. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3.Clin Cancer Res, 2011; 17:7127-38. https://doi.org/10.1158/1078-0432.CCR-11-1157 | |
|
Moreno V, Greil R, Yachnin J, Majem M, Wermke M, Arkenau HT, Basque JR, Nidamarthy PK, Kapoor S, Cui X, Giovannini M. Pharmacokinetics and safety of Capmatinib with food in patients with MET-dysregulated advanced solid tumors. Clin Ther, 2021; 4:6. https://doi.org/10.1016/j.clinthera.2021.04.006 | |
|
Novartis. Tabrecta (Capmatinib) tablets 150 mg, 200 mg. Novartis Pharmaceuticals Corporation. 2020. Available via https://www. hcp.novartis.com/products/tabrecta/met-exon-14-skipping-mutation-nsclc/ | |
|
PubChem. PubChem compound summary for CID 25145656, Capmatinib. National Center for Biotechnology Information, 2021. Available via https://pubchem.ncbi.nlm.nih.gov/compound/Capmatinib | |
|
Saraner N, Karagoz A, Guney B, Saglam O. Determination of Dasatinib in human plasma by using liquid chromatography-tandem mass spectrometry. Int J Anal Bioanal Methods, 2019; 1:2. https://doi.org/10.15761/BRR.1000124 | |
|
Upadhya A, Yadav KS, Misra A.. Targeted drug therapy in non-small cell lung cancer. Clinical significance and possible solutions-Part I. Exp Opin Drug Deliv, 2020; 18(1):73-102. https://doi.org/10.1080/17425247.2021.1825377 | |
|
Vansteenkiste JF, Van De Kerkhove C, Wauters E, Van Mol P. Capmatinib for the treatment of non-small cell lung cancer. Expert Rev Anticancer Ther, 2019; 18(8):659-71. https://doi.org/10.1080/14737140.2019.1643239 | |
|
Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV, Smit EF, Souquet PJ, Vansteenkiste J, Hochmair M, Felip E, Nishio M, Thomas M, Ohashi K, Toyozawa R, Overbeck TR, de Marinis F, Kim TM, Laack E, Robeva A, Le Mouhaer S, Waldron-Lynch M, Sankaran B, Balbin OA, Cui X, Giovannini M, Akimov M, Heist RS, GEOMETRY mono-1 Investigators. Capmatinib in MET Exon 14-Mutated orMET-amplified non-small-cell lung cancer. N Engl J Med, 2020; 383:944-57. https://doi.org/10.1056/NEJMoa2002787 | |
|
Wu YL, Smit EF, Bauer TM. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations. A review of preclinical and clinical studies. Cancer Treat Rev, 2021; 95:102173. https://doi.org/10.1016/j.ctrv.2021.102173 | |
|
Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res, 2016; (5):288-300. https://doi.org/10.21037/tlcr.2016.06.07 | |
|
Zhou C, Tian J, Lin P, Liu T, He A, Fang L, Sun L. Quantitation of Capmatinib, a mesenchymal-epithelial transition factor inhibitor by UPLC-MS/MS in rat plasma and its application to a pharmacokinetic study. Bioanalysis, 2020; 12(5):285-93. https://doi.org/10.4155/bio-2020-0011 | |